Uveitis: Clinical Trials

13 trials for Uveitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Terminated 13
Phase 22Terminated 2

Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior
Phase 3TerminatedEyePoint Pharmaceuticals, Inc.122021-10-132024-12-19
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
intravitreal injection of Conbercept - Uveitis, Macular Edema
Phase 2 / Phase 3TerminatedPeking Union Medical College Hospital52019-10-122022-10-25
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
Placebo, Gevokizumab - Behcet's Disease Uveitis
Phase 3TerminatedXOMA (US) LLC42014-11-012015-12-29
Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
Gevokizumab - Chronic Uveitis
Phase 3TerminatedInstitut de Recherches Internationales Servier712014-08-012020-01-03
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
Dose 2 gevokizumab - Uveitis
Phase 3TerminatedXOMA (US) LLC692014-03-012015-10-16
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis
Phase 3TerminatedXOMA (US) LLC2812012-10-012016-07-12
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis
Phase 3TerminatedXOMA (US) LLC2002012-08-012016-04-08
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
AIN457, Placebo - Non-infectious Uveitis
Phase 3TerminatedNovartis Pharmaceuticals862010-08-012016-01-14
Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema
bevacizumab, triamcinolone acetonide - Uveitis
Phase 3TerminatedHospital Clinic of Barcelona52010-04-012012-03-23
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
AIN457, Placebo - Uveitis
Phase 3TerminatedNovartis Pharmaceuticals302010-04-012015-11-03
38 Week Extension Study to CAIN457C2303
AIN457, Placebo AIN457 - Uveitis
Phase 3TerminatedNovartis Pharmaceuticals592010-03-012016-02-22
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
AIN457, Placebo - Non-infectious Uveitis
Phase 3TerminatedNovartis Pharmaceuticals1252010-02-012015-11-05
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
Dexamethasone - Anterior Uveitis
Phase 2 / Phase 3TerminatedAllergan52006-05-012011-05-30

Narrower conditions

Uveitis, Intermediate (8)  ·  Uveitis, Posterior (8)  ·  Panuveitis (6)  ·  Behcet Syndrome (1)  ·  Cardiovascular Diseases (1)  ·  Dermatitis (1)  ·  Macular Edema (1)  ·  Myocardial Infarction (1)  ·  Psoriasis (1)  ·  Uveitis, Anterior (1)

Broader conditions

Eye Diseases (13)  ·  Uveal Diseases (13)  ·  Panuveitis (4)  ·  Skin Diseases (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Vascular Diseases (2)  ·  Cardiovascular Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Heart Diseases (1)  ·  Hereditary Autoinflammatory Diseases (1)  ·  Infarction (1)  ·  Ischemia (1)  ·  Macular Degeneration (1)  ·  Mouth Diseases (1)

Interventions

secukinumab (4)  ·  gevokizumab (2)  ·  Bevacizumab (1)  ·  Bulk Drugs (1)  ·  Dexamethasone (1)  ·  Triamcinolone Acetonide (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  XOMA (US) LLC (4)  ·  Allergan (1)  ·  EyePoint Pharmaceuticals, Inc. (1)  ·  Hospital Clinic of Barcelona (1)  ·  Institut de Recherches Internationales Servier (1)  ·  Peking Union Medical College Hospital (1)

Countries

United States (10)  ·  Spain (8)  ·  Germany (7)  ·  Israel (6)  ·  United Kingdom (6)  ·  France (5)  ·  Turkey (Türkiye) (5)  ·  Brazil (4)  ·  Greece (4)  ·  Taiwan (4)  ·  Tunisia (4)  ·  Australia (3)  ·  China (3)  ·  India (3)  ·  Italy (3)

Results publications

PMID 23290985, PMID 29370572

NIH funding

2009 (4)